Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stereotactic body radiotherapy and poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a knowledge and attitudes survey in collaboration with the Italian Association of Radiation Oncology (AIRO) and Multicenter Italian Trials in Ovarian Cancer (MITO) groups.
Macchia G, Pezzulla D, Russo D, Campitelli M, Lucci S, Fanelli M, Deodato F, Fagotti A, Gambacorta MA, Savarese A, Pignata S, Aristei C, Ferrandina G. Macchia G, et al. Among authors: russo d. Anticancer Drugs. 2025 Jan 8. doi: 10.1097/CAD.0000000000001684. Online ahead of print. Anticancer Drugs. 2025. PMID: 39784120
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study.
Macchia G, Pezzulla D, Campitelli M, Russo D, Ronzino G, Lucci S, Salutari V, Di Stefano A, Balcet V, Epifani V, Perrucci E, Marchetti C, Distefano MG, Palluzzi E, Autorino R, De Luca V, Giannini R, Rinaldi R, Russo SA, Cilla S, Fagotti A, Gambacorta MA, Scambia G, Deodato F, Ferrandina G. Macchia G, et al. Among authors: russo sa, russo d. Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):465-474. doi: 10.1016/j.ijrobp.2024.09.010. Epub 2024 Sep 8. Int J Radiat Oncol Biol Phys. 2025. PMID: 39255875
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli G, D'Agostino GR, Deodato F, Maranzano E, Ippolito E, Ronchi S, Paiar F, Scorsetti M, Cilla S, Ingargiola R, Huscher A, Cerrotta AM, Fodor A, Vicenzi L, Russo D, Borghesi S, Perrucci E, Pignata S, Aristei C, Morganti AG, Scambia G, Valentini V, Jereczek-Fossa BA, Ferrandina G. Macchia G, et al. Among authors: d agostino gr, russo d. Oncologist. 2020 Feb;25(2):e311-e320. doi: 10.1634/theoncologist.2019-0309. Epub 2019 Oct 10. Oncologist. 2020. PMID: 32043791 Free PMC article.
Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups.
Macchia G, Pezzulla D, Campitelli M, Laliscia C, Fodor A, Bonome P, Draghini L, Ippolito E, De Sanctis V, Ferioli M, Titone F, Balcet V, Di Cataldo V, Russo D, Vicenzi L, Cossa S, Lucci S, Cilla S, Deodato F, Gambacorta MA, Scambia G, Morganti AG, Ferrandina G. Macchia G, et al. Among authors: russo d. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):321-332. doi: 10.1016/j.ijrobp.2023.04.025. Epub 2023 May 6. Int J Radiat Oncol Biol Phys. 2023. PMID: 37150261
Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study.
Cilla S, Campitelli M, Antonietta Gambacorta M, Michela Rinaldi R, Deodato F, Pezzulla D, Romano C, Fodor A, Laliscia C, Trippa F, De Sanctis V, Ippolito E, Ferioli M, Titone F, Russo D, Balcet V, Vicenzi L, Di Cataldo V, Raguso A, Giuseppe Morganti A, Ferrandina G, Macchia G. Cilla S, et al. Among authors: russo d. Radiother Oncol. 2024 Feb;191:110072. doi: 10.1016/j.radonc.2023.110072. Epub 2023 Dec 22. Radiother Oncol. 2024. PMID: 38142932
Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
Macchia G, Cilla S, Pezzulla D, Campitelli M, Laliscia C, Lazzari R, Draghini L, Fodor A, D'Agostino GR, Russo D, Balcet V, Ferioli M, Vicenzi L, Raguso A, Di Cataldo V, Perrucci E, Borghesi S, Ippolito E, Gentile P, De Sanctis V, Titone F, Delle Curti CT, Huscher A, Gambacorta MA, Ferrandina G, Morganti AG, Deodato F. Macchia G, et al. Among authors: d agostino gr, russo d. Gynecol Oncol. 2024 May;184:16-23. doi: 10.1016/j.ygyno.2024.01.023. Epub 2024 Jan 24. Gynecol Oncol. 2024. PMID: 38271773
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial.
Macchia G, Campitelli M, Pezzulla D, Lucci S, Fodor A, Russo D, Balcet V, Bonome P, Durante S, Draghini L, Titone F, D'Agostino GR, Tamburo M, Ferioli M, Ippolito E, Tortoreto F, Caravatta L, De Felice F, Stefano AD, Fanelli M, Cilla S, Cosentino F, Marchetti C, Salutari V, Boccia S, Morganti AG, Gambacorta MA, Fagotti A, Pignata S, Scambia G, Ferrandina G, Deodato F. Macchia G, et al. Among authors: d agostino gr, russo d. Int J Radiat Oncol Biol Phys. 2024 Sep 24:S0360-3016(24)03402-3. doi: 10.1016/j.ijrobp.2024.09.036. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39326506
Ladies project: large database in endometrial cancers for a personalized treatment.
Autorino R, Rinaldi RM, Macchia G, Boccardi M, Mihoci Roshanian I, Sebastiani R, Santo B, Russo D, Ferioli M, Benini A, Perrucci E, Raguso A, Cossa S, Matteucci P, Talocco C, Vicenzi L, Trippa F, Draghini L, Augurio A, Di Guglielmo FC, Cocuzza P, Pistis F, De Felice F, Meregalli S, Bonetto EM, Tamburo M, Bini V, Vavassori A, Gambacorta MA, Aristei C. Autorino R, et al. Among authors: russo d. Radiol Med. 2024 Dec 17. doi: 10.1007/s11547-024-01940-6. Online ahead of print. Radiol Med. 2024. PMID: 39681818
Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Ingrosso G, Detti B, Fodor A, Caini S, Borghesi S, Triggiani L, Trippa F, Russo D, Bruni A, Francolini G, Lancia A, Marinelli L, Di Muzio N, Livi L, Magrini SM, Maranzano E, Musio D, Aristei C, Valeriani M. Ingrosso G, et al. Among authors: russo d. Clin Transl Oncol. 2021 Aug;23(8):1577-1584. doi: 10.1007/s12094-021-02553-5. Epub 2021 Jan 25. Clin Transl Oncol. 2021. PMID: 33495981
Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
Valeriani M, Detti B, Fodor A, Caini S, Borghesi S, Trippa F, Triggiani L, Bruni A, Russo D, Saldi S, Di Staso M, Francolini G, Lancia A, Marinelli L, Di Muzio N, Aristei C, Livi L, Magrini SM, Ingrosso G. Valeriani M, et al. Among authors: russo d. Radiol Med. 2022 Jan;127(1):108-116. doi: 10.1007/s11547-021-01424-x. Epub 2021 Nov 8. Radiol Med. 2022. PMID: 34748151
1,603 results